Aktien Sensor

AstraZeneca has exceeded expectations with a strong Q2 performance, driven by its cancer medicines and a surge in US sales, with shares rising 1% in early trading.

Eurofins Scientific SE’s stock price has surged by nearly 28% in recent days, but investors should be cautious not to get too carried away, as the company’s success is largely dependent on external factors.

Galderma, a leading dermatological treatments and skin care company, achieved a record-breaking 12.2% year-on-year sales growth in the first half of 2025, driven by strong performance from its Cetaphil brand.

Japanese pharmaceutical company Shionogi is expected to report a significant increase in earnings and revenue for Q1, defying the overall market downturn in Japan.

Merck & Co Inc is expected to report a decline in earnings per share for the fourth quarter, amidst market fluctuations and industry challenges.

WuXi AppTec’s stock price has surged 20.6% in revenue and 95.5% in net profit, prompting analysts to rate the company a ‘buy’ and investors to take notice.

Pfizer has finalized a global licensing agreement with 3sbio, Inc., positioning the company for growth in a rapidly expanding pharmaceutical industry.

Merck & Co Inc is set to release its quarterly earnings on July 29, 2025, amidst a growing pharmaceutical industry driven by innovation in cancer research and treatment.

Bristol-Myers Squibb Co. is poised for growth in the thriving pharmaceutical industry, driven by increasing demand for healthcare services and a strong portfolio of products.

Revvity Inc has exceeded earnings expectations, posting strong revenue growth and raising its full-year revenue guidance, despite facing margin pressure in the health science solutions market.